SILENCE THERAP. SP.ADR/1 Net Assets
SILENCE THERAP. SP.ADR/1 net assets. Based on the latest financial reports, SILENCE THERAP. SP.ADR/1 (XRP2) has net assets worth €62.30 Million EUR (≈ $72.84 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€131.44 Million ≈ $153.67 Million USD) and total liabilities (€69.14 Million ≈ $80.83 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore XRP2 net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €62.30 Million |
| % of Total Assets | 47.4% |
| Annual Growth Rate | 52.54% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 222.93 |
Net Assets of SILENCE THERAP. SP.ADR/1 (2021–2025)
Net assets of SILENCE THERAP. SP.ADR/1 from 2021 to 2025. This chart illustrates how SILENCE THERAP. SP.ADR/1's net assets have evolved over time, based on quarterly financial data. See how leveraged is SILENCE THERAP. SP.ADR/1's balance sheet to measure how much of total assets are equity-financed.
Annual Net Assets for SILENCE THERAP. SP.ADR/1 (2021–2025)
The table below shows the annual net assets of SILENCE THERAP. SP.ADR/1 from 2021 to 2025. For live market cap and overall valuation, see market value of SILENCE THERAP. SP.ADR/1.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €62.30 Million ≈ $72.84 Million |
-53.51% |
| 2024-12-31 | €134.02 Million ≈ $156.69 Million |
+509.39% |
| 2023-12-31 | €21.99 Million ≈ $25.71 Million |
-17.66% |
| 2022-12-31 | €26.71 Million ≈ $31.23 Million |
+132.13% |
| 2021-12-31 | €11.51 Million ≈ $13.45 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to SILENCE THERAP. SP.ADR/1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 26164884833.0% over the analyzed period, potentially due to dividend distributions or operating losses.
SILENCE THERAP. SP.ADR/1 Net Assets Breakdown (December 2025)
SILENCE THERAP. SP.ADR/1 net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €624.88 Million | 1002.95% |
| Total Equity | €62.30 Million | 100.00% |
SILENCE THERAP. SP.ADR/1 Competitors by Market Cap
The table below lists competitors of SILENCE THERAP. SP.ADR/1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sichuan Tianwei Electronic Co Ltd
SHG:688511
|
$245.72 Million |
|
888 Holdings plc
F:C8V
|
$245.77 Million |
|
Air Asia Co Ltd
TW:2630
|
$245.79 Million |
|
J.G.CHEMICALS LIMITED
NSE:JGCHEM
|
$245.81 Million |
|
Somany Ceramics Limited
NSE:SOMANYCERA
|
$245.37 Million |
|
CSLM Digital Asset Acquisition Corp III, Ltd
NASDAQ:KOYN
|
$245.36 Million |
|
Kcc Glass Corp
KO:344820
|
$245.26 Million |
|
Journey Energy Inc
TO:JOY
|
$245.05 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SILENCE THERAP. SP.ADR/1's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 134,023,000 to 62,304,000, a change of -71,719,000 (-53.5%).
- Net loss of 88,612,000 reduced equity.
- New share issuances of 15,000 increased equity.
- Other factors increased equity by 16,878,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-88.61 Million | -142.23% |
| Share Issuances | €15.00K | +0.02% |
| Other Changes | €16.88 Million | +27.09% |
| Total Change | €- | -53.51% |
Book Value vs Market Value Analysis
This analysis compares SILENCE THERAP. SP.ADR/1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 15.92x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 54.62x to 15.92x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.13 | €7.00 | x |
| 2022-12-31 | €0.25 | €7.00 | x |
| 2023-12-31 | €0.19 | €7.00 | x |
| 2024-12-31 | €0.95 | €7.00 | x |
| 2025-12-31 | €0.44 | €7.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SILENCE THERAP. SP.ADR/1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -142.23%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -15851.88%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.11x
- Recent ROE (-142.23%) is above the historical average (-214.65%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -462.23% | -317.44% | 0.13x | 11.28x | €-54.34 Million |
| 2022 | -188.44% | -232.44% | 0.17x | 4.87x | €-53.01 Million |
| 2023 | -246.57% | -171.37% | 0.26x | 5.43x | €-56.43 Million |
| 2024 | -33.81% | -104.74% | 0.21x | 1.51x | €-58.71 Million |
| 2025 | -142.23% | -15851.88% | 0.00x | 2.11x | €-94.84 Million |
Industry Comparison
This section compares SILENCE THERAP. SP.ADR/1's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $82,275,373
- Average return on equity (ROE) among peers: -15.87%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SILENCE THERAP. SP.ADR/1 (XRP2) | €62.30 Million | -462.23% | 1.11x | $245.62 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $-294.00K | 0.00% | 0.00x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $141.29 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $19.57 Million | -78.67% | 0.35x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-223.84 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $230.94 Million | -20.03% | 0.13x | $125.74 Million |
| PreveCeutical Medical Inc (18H) | $-3.60 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $538.39 Million | -12.38% | 0.07x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $218.97 Million | -16.25% | 0.03x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $699.56 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $-852.32K | 0.00% | 0.00x | $960.84K |
About SILENCE THERAP. SP.ADR/1
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated … Read more